Risk factors for polyoma virus nephropathy by Prince, Olivier et al.
Nephrol Dial Transplant (2009) 24: 1024–1033
doi: 10.1093/ndt/gfn671
Advance Access publication 10 December 2008
Original Article
Risk factors for polyoma virus nephropathy
Olivier Prince1,2, Spasenija Savic2, Michael Dickenmann3, Ju¨rg Steiger3, Lukas Bubendorf2 and
Michael J. Mihatsch2
1Geriatric Medicine, 2Institute for Pathology and 3Transplantation Immunology and Nephrology, University Hospital Basel,
Switzerland
Abstract
Background. Polyoma virus-associated nephropathy
(PVN) is a common cause of renal transplant failure. The
risk factors for the development of PVN have not yet been
studied in large cohorts of patients for periods of 20 years.
Methods. We collected clinical, renal biopsy and urinary
cytology data from all patients with renal transplantations
performed at the University Hospital of Basel from 1985 to
2005.
All patients with a renal biopsy and urine cytology were
included (n = 880). Renal transplants were divided into
three groups, according to evidence of polyoma virus (PV)
infection (decoy cells in the urine) and biopsy-proven PVN:
1. Renal transplants without evidence of a PV infection
(n = 751).
2. Renal transplants with PV reactivation, e.g. decoy cell
(DC) found by urinary cytology, but without PVN
(n = 90).
3. Renal transplants with PVN (n = 39).
Results. The prevalence of biopsy-proven PVN in this co-
hort of patients was 3.3%. Immunosuppression with my-
cophenolate and/or tacrolimus, ATGAM, male gender of
the recipient and a higher number of transplant rejection
episodes were factors significantly associated with PVN
development.
Conclusions. The most important risk factors for the de-
velopment of PVN are acute rejection and ATGAM used
as induction therapy as well as tacrolimus and mycopheno-
late as maintenance therapy. Therefore, we conclude that
patients with tacrolimus and mycophenolate maintenance
therapy should be carefully monitored for the development
of PVN.
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Introduction
Before 1971, polyoma viruses were considered to be
‘viruses looking for a disease’, till Gardner detected BK-
virus in the urine of a patient with a renal transplant and
suffering from ureteral stenosis [1]. This finding could be
subsequently verified in 3 of 51 patients with ureteral com-
plications [2].
For many years the only documented case of renal in-
fection with BK-virus was that of a child with congenital
immune deficiency syndrome [3]. It has also been known
for a long time that PV can induce haemorrhagic cystitis in
bone marrow transplanted patients [4–8].
In 1971, JC-virus was identified as the cause of multifo-
cal leukoencephalopathy, which is usually fatal [9].
In 1995, BK-virus again became the focus of attention
as the cause of polyoma virus nephropathy (PVN) in renal
transplant recipients [10]. There have been many subse-
quent publications on PVN [11–53], fuelling an ongoing
discussion concerning the causes of the outbreak of PVN;
in particular, the risk factors for acquiring PVN are contro-
versial. PVN can only be reliably diagnosed from a renal
biopsy [11,14,54]. Viral reactivation can be diagnosed by
PCR testing in blood and urine in conjunction with decoy
cell (DC) detection.
The goal of this study was to identify risk factors for
PVN in a series of nearly 900 renal transplant recipients.
They were transplanted between 1985 and 2005, their urine
was screened for DCs and more than 3000 renal biopsies,
performed during periods of functional disturbances, were
available. They all had a minimum of a 1-year follow-up to
exclude later development of PVN. The results showed that,
of all the risk factors studied, medication with tacrolimus
and/or mycophenolate mofetil was the most important fac-
tor where intervention was possible.
Patients, materials and methods
Patients
During the period from January 1985 to January 2005,
1173 renal transplants were done in 1077 patients at the
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UniversityHospital Basel. Patients inwhomno renal biopsy
or urine cytology was available were excluded (n = 293).
None of the excluded patients had PVN.Of the 293 patients,
178 had no urine samples for cytology; the remaining 115
had no biopsies. Of the latter group, 8 nephrectomy spec-
imens and 12 autopsies were available for study, which
showed no signs of PVN. The statistical comparison of all
clinically relevant data showed no significant differences
except for the following: shorter warm and cold ischaemia
times but higher panel reactive antibody (PRA) titres and
shorter survival rates for the excluded patients. All particu-
lars refer to the numbers of transplants and not the numbers
of patients, since some patients received more than one
transplant (n = 56). In total, 880 renal transplants could be
evaluated.
The following data were gathered from all patients ret-
rospectively: sex, age, underlying disease, age at transplan-
tation, age at death, type of donor (post-mortem or liv-
ing donor, degree of family relationship, sex of donor),
HLA mismatch, HLA typing of donor and recipient, PRA
titre (PRA), warm and cold ischaemia time and immune
suppression, both initial and during follow-up. The biopsy
findings at the time of transplantation—zero biopsy—were
also evaluated. The minimum follow-up period was 1 year
(till 1 January 2006). The protocol for immune-suppression
at the time of PVN was studied in a subset of patients.
Materials and methods
Urinary testing was done at varying intervals, usually as
part of the annual control, or for early detection of urothelial
neoplasia in transplanted patients with a known history of
analgetic abuse and later as screening for PVN.Disturbance
of renal function alone was not an indication for urinary
testing.
A sample of 100 ml of freshly collected second morning
urine was centrifuged and either smears (prior to 2003) or
cytospin preparations were stained according to Papanico-
laou. A total of 8104 urine samples were investigated. In
all cases, special attention was paid to the presence of DCs,
which were quantified when present. A semi-quantitative
classification was used: none, few (1–4 DC/10HPF) and
many (>4 DC/10HPF).
The indication for a renal biopsy was nearly always a dis-
turbance of renal function. A total of 3009 renal biopsies
(without time-zero biopsies) were available. The biopsies
were studied according to standard protocols by light mi-
croscopy, immune-histochemistry and in part by electron
microscopy [12].
Starting in 1998, a systematic prospective immune histo-
chemical search of all renal biopsies for SV 40-T-Antigen
(Oncogene, Research Products, San Diego, CA, USA) as
evidence for PVN has been performed. In addition, to avoid
any bias, we performed all biopsies before 1998 in all pa-
tients with DCs in their urine at any time after transplanta-
tion retrospectively immunohistochemistry for SV-40 anti-
gen, cytomegalovirus, Epstein-Barr virus, Herpes simplex
virus I and II and adenovirus antigens.
Based on the results of urinary testing forDCand analysis
of the renal biopsy, three groups could be formed (Table 1
and for details see supplementary table S1): group 1: no DC
no PVN; group 2: few (<4/10HPF) DC, no PVN; group 3:
many DC (>4/10HPF); group 3.1 without PVN; group 3.2
with PVN.
Groups 1 and 2 have been combined in the results section,
since there were no significant differences between these
groups.
Selection of subgroups at the time-point of biopsy
Since PVN manifested at different time-points after trans-
plantation, sub-collectives were formed (designated by S).
The procedure selected was as follows. For each case in
group 3.2 (n = 39) the closest comparable case (matched
control) from groups 1–3.1 was selected, taking into ac-
count the year of transplantation, age, sex and interval be-
tween transplantation and time of peak DC excretion. This
produced three subcollectives that did not differ signifi-
cantly (P > 0.05) according to all the parameters listed in
supplementary table S1 and the parameters for rejection
included in supplementary table S2.
Statistical analysis
All statistical analyses were performed with the aid of the
JMP 5.1 software (SAS Institute Inc., Cary, NC, USA).
The chi-square test and the Mann–Whitney U-test were
applied to compare categorical and continuous variables
when appropriate. Odds ratios for the risk of developing
PVN were calculated from two-by-two contingency tables
(Fisher’s exact test). Multivariate logistic regression analy-
ses were used to identify risk factors for developing a PVN.
The model included only those factors that were found to
be significantly predictive in preceding univariate analyses.
The analysis was performed with stepwise forward logistic
regression (the signicance level for removing the variable
from analysis 0.1, for entering the variables 0.05).
A result was only considered to be significant when the
P-value was <0.01; P-values between 0.05 and 0.01 were
classified as ‘trends to significance’.
Results
Patient collective: demographic and
transplantation-specific characteristics
The collective of 880 patients, with both renal biopsies and
urine analyses, included 519 males (59%) and 361 females
(41%) of mean age 48 years at transplantation and mean
follow-up time of 60 months. The prevalence of PVN in
this collective was 3.3%
There were 766 first transplants (87%) and 100 second
transplants (11%); the remainder had three or more trans-
plants (for details see supplementary table S1).
Of the patients, 551 received cadaver kidneys (63%) and
329 received live donor kidneys (37%); of the latter 1/3
was donor related and 2/3 donor unrelated. Of the cases,
44% were sex matched, 33% were female kidney to male
recipient and 23% vice versa. The mean HLA-mismatch
was 4.6, median 5.0. Only 10% had two or less mismatches,
but more than 60% had five to six mismatches. The mean
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Table 1. Renal biopsies in transplanted patients
All patients with
urine tests and
renal biopsies
Group 1 (DC 0,
PVN negative)
Group 2 (DC 1–4,
PVN negative)
Group 3 (DC >4,
PVN
negative/positive)
Group 3.1 (DC
>4, PVN
negative)
Group 3.2 (DC
>4, PVN positive)
No. of renal grafts (n) 880 595 156 129 90 39
No. of urine examinations
(n)
8104 3922 2060 2122 1275 847
No. of urine examinations
per graft (n)
9.3 ± 9.7 (8.0)∗ 6.7 ± 5.6 (6.0) 13.2 ± 12.7 (10.0) 16.4 ± 14.1 (11.0) 14.2 ± 12.1 (10.0) 21.7 ± 17.0 (12.0)
Interval transplantation—
urine examination in days
860 ± 1275 (355) 923 ± 1354 (357) 984 ± 1369 (371) 623 ± 958 (296) 530 ± 652 (242) 763 ± 1276 (340)
No. of renal biopsies (n) 3009 2011 527 471 284 187
No. of renal biopsies per
graft (n)
3.4 ± 1.7 (3.0) 3.4 ± 1.7 (3.0) 3.4 ± 1.6 (3.0) 3.6 ± 1.7 (3.0) 3.1 ± 1.5 (3.0) 4.8 ± 1.8 (5.0)
Interval transplantation—
renal biopsies (without
time-zero biopsies)
656 ± 1084 (173) 698 ± 1116 (175) 759 ± 12 667
(176)
378 ± 596 (155) 457 ± 712 (147) 266 ± 350 (157)
1–6774 1–6360 1–6774 2–3509 2–3509 5–2269
Biopsies taken at
transplantation n (%)
521 (17) 374 (19) 89 (17) 58 (12) 43 (15) 15 (8)
∗Mean, SD (median).
DC = decoy cells, PVN = polyomavirus-associated nephropathy.
PRA-titre was low at 4.2%. The mean cold ischaemia time
was 666 min; the mean warm ischaemia time was 2.7 min.
Patient groups 1 (no DC) and 2 (few, 1–4 DC) showed no
difference by univariate analysis and were therefore com-
bined (see supplementary table S1). A comparison between
groups 1 and 2 combined and group 3 (many DC) revealed
that DC were more frequent in men as well as in recipients
of non-related grafts. When the comparison was restricted
to group 3.2, it could be seen that kidneys from living
donors, particularly non-related, were risk factors for PVN.
Comparison between sub-groups 3.1 and 3.2 produced a
similar result.
In 23 cadaver kidney transplants, both kidneys from a sin-
gle donor were transplanted in Basel. Six of these transplant
recipients from three kidney donors had similar findings:
many DC in urine (group 3). Forty recipients receiving sin-
gle kidneys from the other 20 kidney pairs were assigned to
different groups in respect of DC excretion (groups 1–3.2).
The only significant risk factor found was the sex of the
recipient (male) (P = 0.001); all other parameters studied
were not relevant. Due to the contemporaneous transplan-
tation of the kidney pairs, practically all received the same
therapy, so that no statement concerning therapy modality
as a risk factor is possible.
In conclusion, an increased risk of strong reactivation of a
polyomavirus infectionwith/without PVNwas seen inmale
patients and in recipients of living donor kidneys, especially
those from non-related donors. All other parameters did
not have a significant influence on reactivation of polyoma
virus with excretion of many DC, with/without PVN.
Immune suppression
Initial immune suppression. Immune suppression proto-
colswere subject tomany changes over the years concerned.
This is reflected in supplementary table S3, where the im-
mune suppressives employed at the time of transplantation
are summarized.
Induction therapy was usually done with antithymocyte
antigens (ATG)/antilymphocyte antigens (ALG) (n = 302)
or IL-2 receptor-directed antibodies (basiliximab, da-
clizumab) (n = 133); 370 patients received no induction
therapy.
The most common basis immune-suppressive drug used
was cyclosporin (CyA) (n = 662), followed by tacrolimus
(Tac) (n = 138) and rapamycin (Rapa) (n = 65). Co-
medication was usually done with azathioprine (Aza)
(n = 563) and less frequently with mycophenolate mofetil
(MMF) (n = 296). Co-medication with steroids was done
in practically all cases and therefore steroid therapy was not
taken into further consideration.
Therapy with tacrolimus and MMF (Table 2) was as-
sociated with a risk for many DC in urine (group 3).
ATGAM, IL-2 receptor-directed antibodies (basiliximab,
daclizumab) and MMF were risk factors for PVN (groups
1 and 2 versus 3.2).
A total of 11 different therapy schemes were de-
fined, taking into account the induction therapy, basis im-
mune suppression and co-medication (excluding steroids)
(supplementary table S4). In 39 patients combinations of
medicaments were used that <1% of all patients received;
these were not considered further. The most frequent ther-
apy schemes were ALG-CyA-Aza (n = 276), CyA-MMF
(n = 125) and CyA monotherapy (n = 115).
In respect of induction therapy (groups 1 and 2 versus 3 or
3.1), only the use of ATGAM was associated with a clearly
increased risk of polyoma virus reactivation. The risk of
reactivation was increased significantly with tacrolimus
as basis immune suppression and MMF a co-medication
(Table 3). The appearance of PVN itself was associated
with ATGAM and/or tacrolimus therapy.
The importance of tacrolimus and/or MMF can be seen
when the relative frequencies of these therapy forms in
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Table 2. Relation between DC excretion and individual substances
Initial immunosuppressive
therapy
Groups 1 and 2 versus
group 3
Groups 1 and 2
versus group 3.1
Groups 1 and 2
versus group 3.2
Group 3.1 versus
group 3.2
P OR P OR P OR P OR
Induction therapy
ATG versus no ATG <0.0001 0.3 0.0015 0.4 <0.0001 0.1 0.0138 0.2
ATGAM versus no
ATGAM
0.0377 2.3 0.6456 1.3 0.0037 5.1 0.042 3.9
OKT-3 versus no OKT-3 0.1737 0.5 0.5153 0.7 0.0533 0.1 0.1388 0.1
IL-2 receptor directed
antibodies versus no
0.0942 1.5 0.8127 0.9 0.0011 3.4 0.0045 3.6
Induction therapy versus
no induction
0.0046 0.6 0.0014 0.5 0.6642 0.9 0.1379 1.8
ATG versus no induction <0.0001 0.3 0.0004 0.4 0.0005 0.1 0.1124 0.3
ATGAM versus no
induction
0.2050 1.7 0.8334 0.9 0.0132 4.1 0.0286 4.6
OKT3 versus no induction 0.0619 0.4 0.198 0.6 0.0531 0.1 0.1982 0.1
IL-2 receptor directed
antibodies versus no
induction
0.8205 1.1 0.1881 0.6 0.0296 2.3 0.0079 3.6
Basis immune suppression
CyA versus no <0.0001 0.4 0.0009 0.4 0.0109 0.4 0.8199 0.9
Tacrolimus versus no <0.0001 2.5 0.0004 2.6 0.0526 2.2 0.7042 0.8
Rapamycin versus no 0.5986 1.2 0.8539 0.9 0.2306 1.9 0.2659 2.1
Co-medication
Aza versus no 0.0001 0.5 0.0177 0.6 0.0041 0.4 0.4536 0.8
MMF versus no 0.0001 21.5 0.0035 1.9 0.0041 2.6 0.4536 1.3
ATG = antithymocyte globulin, ALG = antilymphocyte globulin, IL-2-RA = IL-2 receptor-directed antibodies (basiliximab and daclizumab), CyA =
cyclosporin-A, Tac = tacrolimus, Rapa = rapamycin, Aza = azathioprine, MMF = mycophenolate mofetil, DC = decoy cells, PVN = polyomavirus-
associated nephropathy, OR = odds ratio.
Table 3. Relation between the presence of DC in urine and various combination therapies
Initial immunosuppressive therapy Groups 1 and 2
versus group 3
Groups 1 and 2
versus group 3.1
Groups 1 and 2
versus group 3.2
Group 3.1 versus
group 3.2
P OR P OR P OR P OR
CyA-Aza (without induction) compared with
Alg/ATG-CyA-Aza 0.1226 2.5 0.0137 6.9 0.1955 0.2 0.0192 0.1
ATGAM-CyA-Aza <0.0001 15.0 0.0034 17.9 0.0008 13.4 0.8340 0.8
OKT3-CyA-Aza 0.1855 3.1 0.0360 9.3 0.2929 0.1 0.0507 0.1
Tac-Aza (without induction) compared with
IL-2-RA-Tac-Aza 0.1425 0.3 0.0132 0.1 0.8376 0.8 0.1425 6.3
CyA-MMF (without induction) compared with
Alg/ATG-CyA-MMF 0.5527 0.6 0.3340 0.4 0.6979 1.6 0.3641 4.0
IL-2-RA-CyA-MMF 0.7678 0.9 0.1588 0.5 0.1334 2.4 0.0296 4.7
Rapa-MMF (without induction) compared with
IL-2-RA-Rapa-MMF 0.4718 1.6 0.9314 0.9 0.2091 3.7 0.2945 4.0
CyA-Aza (without induction) compared with
Tac-Aza (without induction) <0.0001 17.5 <0.0001 39.8 0.0118 6.3 0.1425 0.2
CyA-MMF (without induction) <0.0001 11.8 <0.0001 28.3 0.1001 3.5 0.0996 0.1
Rapa-MMF (without induction) compared with
CyA-MMF 0.1849 0.5 0.1950 0.5 0.6353 0.6 0.8200 1.3
ATG = antithymocyte globulin, ALG = antilymphocyte globulin, IL-2-RA = IL-2 receptor-directed antibodies (basiliximab and daclizumab), CyA =
cyclosporin-A, Tac = tacrolimus, Rapa = rapamycin, Aza = azathioprine, MMF = mycophenolate mofetil, DC = decoy cells.
groups 1 and 2, as well as 3.1 and 3.2, are considered
(supplementary table S4). In groups 1 and 2 only 42% of
the patients received one or both substances, compared to
73% in group 3.1 and 77% in group 3.2.
In summary, the findings speak for an increased risk
of viral reactivation with/without PVN with the use of
ATGAM as induction therapy, with tacrolimus as basis im-
mune suppression and with MMF co-medication. All other
therapy schemes were only associated with low risks.
Immune suppressive maintenance therapy. To help judge
the value of the findings concerning the importance of the
initial immune suppression for the reactivation of polyoma
virus, the immune suppressive maintenance therapy was
studied in a subgroup of groups 1 and 2-S, as well as 3.1-S
and 3.2-S.
In our cases, PVN was diagnosed after a mean period of
283± 232 days (median: 196, range 42–982). Thus, the ini-
tial immune suppression can only give limited information
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Table 4. Relation between DC excretion and PVN with different treatment combinations in subgroups
Therapy combinations Group 1/2-S versus
group 3-S
Group 1/2-S
versus group 3.1-S
Group 1/2-S versus
group 3.2
Group 3.1-S
versus group 3.2
P OR P OR P OR P OR
Rapa-(CyA)-MMF versus CyA-Aza/CyA only 0.1819a 4.7 0.3022a 3.5 0.2264 1.2 0.4722a 0.3
Rapa-(CyA)-MMF versus CyA-MMF 0.1907 0.4 0.4198 0.5 0.1384 4.5 0.4500 2.4
Rapa-(CyA)-MMF versus Tac-MMF 0.0632 1.5 1.000a 1.0 0.0086a 21.0 0.0293a 21.0
CyA-Aza/CyA only versus CyA-MMF 0.0065 11.8 0.0503 6.5 0.0093 5.3 0.6140 1.6
CyA-Aza/CyA only versus Tac-Aza <0.0001 47.3 0.0026 21.0 <0.0001 26.3 0.2091 2.5
CyA-MMF versus Tac-MMF 0.0028 28.0 0.6140 0.5 0.0618 4.7 0.0234 8.8
Tac-Aza versus Tac-MMF 0.5917 0.6 0.1698a 0.2 0.9440 0.9 0.0805 5.6
aSmall numbers.
ATG = antithymocyte globulin, ALG = antilymphocyte globulin, IL-2-RA = IL-2 receptor-directed antibodies (basiliximab and daclizumab), CyA =
cyclosporin-A, Tac = tacrolimus, Rapa = rapamycin, Aza = azathioprine, MMF = mycophenolate mofetil, DC = decoy cells, PVN = polyomavirus-
associated nephropathy.
about the relationship between immune suppression at the
time of biopsy and the extent of polyoma virus reactivation.
Complications following rejection crises, drug intolerance,
etc. frequently necessitated changes in the type of immune
suppression. Groups 1 and 2-S on one hand and 3.1-S and
3.2-S on the other hand differ only in respect of therapy;
there were no significant differences (P> 0.1) in any of the
other parameters studied, including renal biopsy findings.
Analysis of the individual immune suppressive agents
employed showed that of all maintenance therapies used,
tacrolimus (but not MMF) is associated with an increased
risk of pronounced viral reactivationwith/without PVN (the
significance for MMF was not seen in our small subgroup
analysis). In addition, bolus therapy with steroids is also
linked to an increased risk for PVN (see supplementary
table 5S).
The therapy schemes most frequently employed included
tacrolimus and/or MMF. In group 1/2-S, 77% received
tacrolimus and/or MMF; in group 3.1-S, 95% and in group
3.2, 100% (supplementary table S6). Of the treatments used
(Table 4), CyA-MMF, Tac-Aza and Tac-MMF appear to be
particularly high-risk combinations.
Analysis of serum drug concentrations (see supplemen-
tary table S7) revealed a borderline significance between
tacrolimus levels and a marked reactivation of polyoma
virus, with/without PVN. In group 1/2-S, the median level
of tacrolimus was 11.5 and in groups 3.1-S and 3.2-S, 17.9
and 18.0 ng/ml, respectively.
For CyA levels between 300 and 500 µg/l (median), ra-
pamycin levels between 15 and 20 µg/l (median), MMF
levels between 4 and 5 mg/l (median) and total steroid
dosage between 2 and 3 g (median), there were no signifi-
cant differences (P > 0.01) between the groups in respect
of viral reactivation/PVN.
In summary, analysis of maintenance immune suppres-
sion revealed an association between tacrolimus and/or
MMF and PV reactivation with/without PVN.
Renal biopsy findings in relation to DC excretion. The
most common findings were interstitial rejection or cal-
cineurine inhibitor toxicity, each in ∼50% of the trans-
plants.
Patients in group 3, which is with strong reactivation of
polyoma virus with/without PVN, had interstitial rejection
significantly more frequently and revealed signs of a hu-
moral rejection reaction with transplant glomerulitis (see
supplementary table S2).
A time-zero biopsy at the time of transplantation was
available in 58% of the patients (n = 511). Pre-existing
damage to the donor kidney had no influence on DC excre-
tion.
Comparison of the sub-groups 3.1 or 3.2 (manyDC,with-
out/with PVN) with the group without/few DC revealed a
trend towards more vascular and interstitial rejection in
group 3.1, but a highly significant number of cases of hu-
moral rejection in group 3.2 (signalled by C4d positiv-
ity in peritubular capillaries) sometimes with and some-
times without transplant glomerulitis (see supplementary
table S2). Also in patients with many DC in urine (group
3), pre-existing damage to the donor kidney had no influ-
ence on the subsequent development of PVN.
In summary, it can be stated that rejection crises of all
types are associated with PVN, particularly in group 3.2,
and very frequently exhibit characteristics of humoral rejec-
tion (transplant glomerulitis, C4d positivity in peritubular
capillaries). Of interest, calcineurine inhibitor nephrotoxic-
ity and pre-existing renal damage had no obvious relevance.
Summary of risk factors: correlation of risk factors with
each other and results of multi-variate analysis. The re-
sults of the multivariate Cox regression analysis of possible
factors influencing PV reactivation as well as manifesta-
tion of PVN are summarized in Table 5. The results show
no differences when all parameters, or only those param-
eters significant in the univariate analysis, are considered.
The most important factors that favour a reactivation of
the PV infection and/or manifestation of PVN are sex of
recipient (male), non-related live donor, tacrolimus, MMF
and ATGAM treatment, and rejection reactions (rejection
score: interstitial, vascular rejection, transplant glomerulitis
and C4d positivity in peritubular capillaries). Manifestation
of PVN (no PVN versus PVN) is also favoured by the same
factors, with the exception of sex of recipient and the pa-
rameter: non-related donor.
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Table 5. Multivariate Cox regression analyses
Group 3 versus groups 1 and 2
(n = 880)
PVN (group 3.2) versus no PVN
(groups 1, 2 and 3.1) (n = 880)
PVN (group 3.2) versus DC high
(group 3.1) (n = 129)
Risk factor Hazard ratio (95% CI) P Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Male recipient 2.2 (1.5–3.3) 0.0001 1.5 (0.7–3.1) 0.2621 0.7 (0.3–1.5) 0.3418
Unrelated living donor 1.9 (1.1–3.4) 0.0271 2.0 (0.8–5.4) 0.1442 1.2 (0.4–3.2) 0.7249
ATGAM 2.9 (1.4–5.7) 0.0027 6.6 (2.3–18.9) 0.0005 2.9 (0.8–10.5) 0.1106
Tacrolimus 4.8 (3.1–7.3) 0.0000 3.3 (1.5–7.6) 0.0038 1.4 (0.5–3.9) 0.4715
MMF 4.6 (3.1–6.7) 0.0000 3.5 (1.6–7.5) 0.0013 2.2 (0.8–5.6) 0.1046
Acute rejection 1.9 (1.3–2.9) 0.0010 5.1 (1.8–14.6) 0.0021 3.1 (1.1–9.2) 0.0368
MMF = mycophenolate mofetil, DC = decoy cells, PVN = polyomavirus-associated nephropathy.
Fig. 1. Biopsies with/without PVN in relation to therapy in a 20 year period in Basel CyA = cyclosporin-A, MMF = mycophenolate mofetil, PVN =
polyomavirus-associated nephropathy.
The odds ratios for therapy-associated factors were
higher than transplant-specific factors, which may indicate
greater importance.
Discussion
This is a retrospective analysis of all renal transplanta-
tions performed in Basel between 1985 and 2005 in which
urine samples (>8000) were studied for DCs and biopsies
(>3000) were performed in case of renal dysfunction. To
avoid any bias, all biopsies of patients having DCs in their
urine were retrospectively stained for SV40 to prove or
exclude BK-virus.
Primarily, all patients, finally excluded (n = 293), with
urine samples but no biopsies or biopsies but no urine sam-
ples for cytology were included in the evaluation without
any difference to the results described in this paper. Of note,
no patients with PVN were excluded from the analysis.
The prevalence of PVN in this series was 3.3%, which
is in the range reported by other investigators (1.1–9.3%)
[23,24,30,32,36,55–62]. Our study covered the highest
number of potential risk factors studied to date. Of note,
multivariate analysis revealed that only three groups of fac-
tors were significantly associated with the reactivation of
a polyoma virus infection and particularly PVN: immune
suppression, rejection and male gender of transplant recip-
ients and non-related live donor kidneys.
Regarding immune suppression after transplantation, all
commonly used substances and combinations thereof were
evaluated. Here, it appeared that only three immune sup-
pressives favoured development of PVN: tacrolimus, MMF
and the now uncommon ATGAM. All other immune sup-
pressives in common use, particularly cyclosporin, azathio-
prine, rapamycin,ALGand specific anti-lymphocyte prepa-
rations had no obvious influence on the development of
PVN. During application of the latter substances, PVN was
not observed, although there was some reactivation of PV.
This result was obtained from analysis of all patients, taking
the initial immune suppression into account, as well as from
analysis of a sub-collective in which the maintenance ther-
apy was followed up for a mean of 9.4 months (median 7.7)
after transplantation. Only in the case of tacrolimus, not for
the other immune suppressives, did rising blood levels in-
crease the risk of strong PV reactivation with/without PVN.
The results of previous publications on therapy regimes as
particular risk factors for PVN have been conflicting.
Depending on the study, 50–100% of patients with
PVN had received tacrolimus and 40–97% MMF [15,21–
24,30,32,43,55–61,63–68]. This encouraged many au-
thors to regard tacrolimus or MMF as risk factors
[12,13,20,54,55,69,70]. PVN develops only rarely in pa-
tients receiving neither tacrolimus nor MMF (39 patients
[2,24,35,36,55,56,61,63]). This includes a report from India
[36], in which a high frequency of PVN (30 cases, preva-
lence 10%) was found in patients not receiving tacrolimus
or MMF. A further study describes six patients with PVN
not given tacrolimus, but no information regarding co-
medication with MMF was given [66]. Others found that
tacrolimus, but not MMF, was a risk factor [67]. Two large
studies from the USA with over 1000 kidney recipients did
not identify any particular form of immune suppression,
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including tacrolimus and MMF, as risk factors [36,47,66].
These contradictory results can be explained by the fact
that the time periods covered were short and particular im-
mune suppressives were favoured during this period. In our
patients 662/880 received CyA, 138/880 tacrolimus and
65/880 rapamycin as basis immune suppression; 296/880
received MMF in addition. It is noteworthy that only 9/880
patients without either tacrolimus or MMF initially devel-
oped PVN. Of these nine patients, seven later received
tacrolimus and MMF, one only tacrolimus and one only
MMF. In the whole series of kidney transplant recipients,
50% received tacrolimus, 40% cyclosporine and 7% ra-
pamycin. If immune suppressive therapy is irrelevant for
the development of PVN, a much higher number of cases
of PVN with cyclosporin and rapamycin therapy could be
expected. Incidentally, the first case of PVN in Basel was
diagnosed on 1 October 1997, approximately 1 year af-
ter the introduction of tacrolimus (April 1996, see Fig. 1).
This strongly suggests that tacrolimus and MMF, but not
other frequently used immune suppressive agents, increase
the risk of polyoma virus reactivation and subsequent PVN
[45]. The risk is further increased when tacrolimus, MMF
with prednisone and additional anti-lymphocyte prepara-
tions are combined. This proves that PVN only manifests
under immune suppression. Although there was a tempo-
ral coincidence between the introduction of the new, potent
immune suppressives tacrolimus and MMF and the appear-
ance of PVN, it can be assumed that the higher intensity of
immune suppression with tacrolimus and MMF was deci-
sive, rather than an additional effect of a particular class of
substances [13,14,25,47,71,72]. This assumption remains
controversial [61] but is supported by the association be-
tween dosage and/or blood level and risk of PVN [73]. A
tacrolimus level exceeding 8 ng/ml [38,55] or a MMF-dose
of over 2 g/day were associated with an increased risk for
PVN [55].
The second important risk factor identified in this study
was a rejection episode. By multivariate analysis, intersti-
tial cellular rejection and transplant glomerulitis were par-
ticularly important. However, due to the odds ratio, their
importance must be placed lower than the therapy. This
statement must be generalized to be meaningful; it does not
mean that other forms of rejection are not associated with a
higher risk, rather that severe rejection episodes, regardless
of type, increase the risk of PVN, as shown by the univariate
analysis (see Table 5). This suggests that a severe rejection
crisis is a therapy-independent factor that promotes the de-
velopment of PVN. It can also be postulated that increased
tubular epithelial regeneration, following tubular necrosis
caused by rejection, contributes to the reactivation of poly-
oma virus infection, a viewpoint also previously favoured
by the authors [13,17].
Interestingly acute tubular necrosis caused by both cold
and warm ischaemia is also associated with accelerated re-
generation of the tubular epithelium but does not favour
the development of PVN, since then PVN should develop
early after transplantation and not many months later. Also,
severe, recurring episodes of rejection often necessitated
the use of high dose tacrolimus and MMF as so-called res-
cue therapy. In line with this observation is the fact that
patients with strong reactivation, with/without PVN, re-
ceived more steroid boluses and hence a higher cumulative
Table 6. Summary of risk factors mentioned in the literature
Risk factors Significant risk factor Not a risk factor
Patient-specific risk
factors
Recipient older than
50 years
[1–3] [4–7]
White ethnicity [3,8,9] [4,5]
Male recipient [2,3,9] [1,4–7,10–16]
Previous rejections [6,17–20] [1,2,4,5,7,9–12,14,
15,21–25]
Ureteral stents [23]
BKV serostatus [10,15,26,27]
Disturbances of
interferon
γ-metabolism
[28–30]
Diabetes mellitus [3,11,31,32] [1,2,4, 7]
CMV infection [19,21,33] [7,25]
Graft-specific risk factors
HLA mismatch [5,6,17] [1,2,4,6,14,34]
Tacrolimus toxicity [3] [5]
Female donor [1] [4]
Lack of HLA C7 [34]
Virus-specific risk
factors
[35,36]
dose of steroids. Other authors also reported that many pa-
tients had received therapy for rejection episodes before
the diagnosis of PVN [14,21,23,55]. This is particularly
impressive in patients given ATGAM initially, as shown
in our study to be a risk factor. Unpublished results from
Basel showed that patients given ATGAM suffered much
more frequently from severe rejection crises than patients
given ATG, which made a change to tacrolimus therapy
necessary. Interestingly, calcineurine inhibitor nephrotoxi-
city did not correlate with PVN. In calcineurine inhibitor
nephrotoxicity (CIN) tubular necroses are also seen, with-
out any significant increase in PVN. Taken together, tubu-
lar cell necrosis per se is unlikely to play a role as a co-
factor in polyoma virus infection. According to the opin-
ion of earlier investigators [21,55], including ourselves,
acute rejection is an independent risk factor, although other
studies couldn’t demonstrate a direct association between
rejection and PVN [14,15,19,24,30,32,38,43,45,61,65,66,
73,74].
Multivariate analysis revealed that male gender of trans-
plant recipients is an independent risk factor, which
concurs with previous reports [24,38,56]. However, sev-
eral other studies did not reveal a preference for males
[14,15,30,47,55,61,66]. These differences might be expli-
cable by differences between the groups studied. In our
series rank-correlation analysis revealed a close, complex
relationship between male recipients, living donor kidneys
and non-related live donors.
Such complex correlations might explain why a further
study found that kidneys from female donors were an in-
dependent risk factor [66], which was neither confirmed in
another study [73], nor by us. The same holds true for HLA
mismatches. In three studies, the extent of HLA-mismatch
was reported to be an independent risk factor [23,43,55]
while the majority of studies, including our own, speak
against an association between HLA-mismatch and PVN
[24,46,55,61,73]. CIN did not play any role in our collec-
tive, in contrast to other reports [43,56]. Diabetes mellitus
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is commonly considered to promote PVN, an opinion that
others and we could not confirm (see Table 6).
In summary, we conclude that immune suppression per
se promotes reactivation of polyoma virus. Tacrolimus and
MMF carry an increased risk for PVN. This is evidenced
in our series as the relative frequency of tacrolimus and/or
MMF therapy, taking the initial therapy into account, in-
creases from 30% in group 1 (noDC) to 50% in group 2 (<4
DC/HPF) to 75% in group 3 (>4 DC/HPF). When mainte-
nance therapy was considered, all of the patients with PVN
had received tacrolimus and/or MMF. Furthermore, the
tacrolimus blood level was associated with the development
of PVN. A tacrolimus level exceeding 20 ng/ml appears to
be associated with a particularly high risk. The MMF level
could also play a role but was not apparent in this study.
Thus, not a particular drug class but the higher immune sup-
pressant potential ismost likely responsible for the outbreak
of PVN in recent years. A rejection episode is an indepen-
dent risk factor that increases the risk of PVN probably
through subsequent intense immune suppression since be-
fore the introduction of tacrolimus and/or MMF, PVN was
never seen in our patients. The various recipient and donor
characteristics, such as male recipients, live donor kidneys
and non-related, living donors, are also associated with a
higher risk to rejection, but they probably play a secondary
role. Finally, we wish to point out that other factors, factors
e.g. including viral status of the recipient, white ethnicity,
ureteral stents, disturbances of interferon γ-metabolism and
lack of HLAC7, which have been discussed in the literature
but not studied by us, should not be ignored.
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